Ontegimod is under clinical development by 149 Bio and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ontegimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ontegimod overview

Ontegimod is under development for the treatment of lupus nephritis. It is administered through oral route. The drug candidate acts by targeting integrin alpha-M (ITGAM/CD11b) and CD18 (integrin beta2).

It was also under development for the treatment of gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, colorectal cancer, prostate cancer, gastric cancer, esophageal cancer, triple negative breast cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, renal cell carcinoma, hepatocellular carcinoma and newly diagnosed stage IV pancreatic cancer. 

149 Bio overview

149 Bio is a biotechnology company that involved developing breakthrough medicines and therapies for the treatment of kidney diseases. The company is headquartered in Miami, Florida, the US.

For a complete picture of Ontegimod’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.